FDA clears IND for Telomir-Zn in advanced triple-negative breast cancer; Phase 1/2 trial planned for 1H 2026

Telomir Pharmaceuticals, Inc.

FDA cleared IND for lead candidate Telomir-Zn in advanced/metastatic triple-negative breast cancer.
Phase 1/2 trial to enroll ~76 patients; Phase 1 dose-escalation, Phase 2 primary endpoint ORR.
Planned initiation in first half of 2026 at a leading US academic medical center.
Preclinical data included pharmacology, toxicology, PK, and biomarker analyses.
Translational biomarker program to assess epigenetic modulation and telomere dynamics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.